Posts Tagged ‘CKD’

RSS

March 4th, 2014

AF Patients with Chronic Kidney Disease Also Benefit from Warfarin

Anticoagulation is a cornerstone of therapy for atrial fibrillation because it lowers the heightened risk for stroke in this population. People with chronic kidney disease are also at increased risk for stroke, but the benefits of anticoagulation are less clear in this group, and anticoagulation is used less often in AF patients who have CKD. […]


December 11th, 2013

Inside The KDIGO Guideline On Lipid Management In Patients With CKD

and

Recently the Kidney Disease Improving Global Outcomes (KDIGO) Lipid Management in Patients with Chronic Kidney Disease Guideline was published in Kidney International. Now a synopsis has appeared in the Annals of Internal Medicine. Harlan Krumholz spoke with the co-chairman of the guideline, Marcello Tonelli. Krumholz: Like the new US Guidelines, the KDIGO Guideline abandons targets. Were you aware of the US Guidelines or did […]


June 19th, 2012

Is Chronic Kidney Disease a CHD Risk Equivalent?

A study published in the Lancet provides new data about whether chronic kidney disease (CKD) should, like diabetes, be considered a coronary heart disease (CHD) risk equivalent. Marcello Tonelli and colleagues analyzed data from a population of 1.25 million people in Alberta, Canada. During a median follow-up of 4 years, 11,340 people were admitted to the hospital […]


October 31st, 2011

FDA Gives Favorable Review to SHARP Ahead of Vytorin Advisory Panel

In preparation for Wednesday’s meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee, an FDA reviewer has generally endorsed the positive interpretation of the SHARP trial of Vytorin (ezetimibe and simvastatin) in chronic kidney disease (CKD). Based on the results of SHARP (Study of Heart and Renal Protection), Merck is seeking an expansion of its […]


June 8th, 2011

SHARP Results Published in Lancet

The main results of SHARP (Study of Heart and Renal Protection) have now been published in the Lancet, following their preliminary presentation last November at the American Society of Nephrology meeting. The results are also posted online on the trial’s website. In brief, SHARP randomized 9270 patients with chronic kidney disease (CKD) — one-third of whom were on […]


November 22nd, 2010

SHARP: A Tale of Two Press Releases

Two press releases were issued about the SHARP trial : one from Merck, the much-maligned and criticized manufacturer of Vytorin (the combination of ezetimibe and simvastatin), and one from the group running the trial, the highly-respected Clinical Trials Service Unit (CTSU) at Oxford. Here’s the surprise: compared to the Oxford press release, the Merck release is a paragon, […]


November 20th, 2010

SHARP Shows Benefit for Vytorin in Chronic Kidney Disease

The long-awaited SHARP study has turned up positive results for Vytorin (ezetimibe and simvastatin) in a population of patients with chronic kidney disease. Results of SHARP (Study of Heart and Renal Protection) were presented on Saturday at the American Society of Nephrology meeting in Denver and were scheduled to be posted online on the trial’s website. SHARP compared […]


September 15th, 2010

TREAT Analysis: Target Dosing Is Tricky

A new analysis of TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) is raising questions about the use of target-based strategies for the treatment of anemia in people with chronic kidney disease. (Last year, the main TREAT results showed that treatment with darbepoetin alfa was not beneficial – and was associated with an increase in the […]


September 1st, 2010

Long-Term Effect of Intensive BP Control in Blacks

The African-American Study of Kidney Disease and Hypertension (AASK) investigated the role of intensive blood-pressure control in slowing the progression of chronic kidney disease in black patients. In the previously reported results of the randomized portion of AASK, intensive BP control had no effect on the progression of CKD. Now the AASK Collaborative Research Group reports the […]